US Patent Issued to AB SCIENCE on June 9 for "Masitinib for the treatment of castrate-resistant prostate cancer" (French Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,648,944, issued on June 9, was assigned to AB SCIENCE (Paris).

"Masitinib for the treatment of castrate-resistant prostate cancer" was invented by Alain Moussy (Paris) and Colin Mansfield (Paris).

According to the abstract* released by the U.S. Patent & Trademark Office: "Masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof. In particular, masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of mCRPC in a subject suffering from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or low...